Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Rituximab in Muscular Dystrophy, Duchenne: NCT07475754 Clinical Landscape Report 2026
16 September 2026
NCT07475754 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Retifanlimab in Glioblastoma, IDH-Wildtype: NCT07468136 Clinical Landscape Report 2026
16 September 2026
NCT07468136 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Panitumumab-IRDye800CW(Stanford University) in Pituitary Adenoma: NCT07493447 Clinical Landscape Report 2026
16 September 2026
NCT07493447 clinical landscape for Pituitary Adenoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IL13Rα2 + EGFR/EGFRvIII Dual-Target CAR-NK(Beijing Biotech) in High grade glioma: NCT07480941 Clinical Landscape Report 2026
16 September 2026
NCT07480941 clinical landscape for High grade glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Autologous total tumor mRNA and pp65 fl LAMP mRNA loaded DOTAP liposome vaccine(University of Florida) in Recurrent Medulloblastoma: NCT07492316 Clinical Landscape Report 2026
16 September 2026
NCT07492316 clinical landscape for Recurrent Medulloblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HW252001 in Idiopathic Pulmonary Fibrosis: NCT07493031 Clinical Landscape Report 2026
16 September 2026
NCT07493031 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JL-15003 in Recurrent Glioblastoma: NCT07501559 Clinical Landscape Report 2026
16 September 2026
NCT07501559 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iloprost in Vaso-occlusive crisis: NCT07498309 Clinical Landscape Report 2026
16 September 2026
NCT07498309 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
UCL70805F in CD70 positive Renal Cell Carcinoma: NCT07500805 Clinical Landscape Report 2026
16 September 2026
NCT07500805 clinical landscape for CD70 positive Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
JL-15003 in Recurrent Glioblastoma: NCT07497373 Clinical Landscape Report 2026
16 September 2026
NCT07497373 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Metastatic Renal Cell Carcinoma: NCT07500831 Clinical Landscape Report 2026
16 September 2026
NCT07500831 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Talquetamab in Myasthenia Gravis: NCT07499323 Clinical Landscape Report 2026
16 September 2026
NCT07499323 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.